Drug analysis: Erbitux

Drug analysis: Erbitux

  • December 2017 •
  • 34 pages •
  • Report ID: 5336368 •
  • Format: PDF
Drug Overview
Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA) is a chimeric monoclonal antibody (MAb) that binds to the extracellular domain of epidermal growth factor receptor (EGFR). The receptor is involved in the regulation of cell growth, proliferation, and differentiation.

Erbitux is composed of the Fv regions of a murine EGFR MAb-specific for the N-terminal portion of human EGFR with human immunoglobulin G1 heavy and k-light chain constant regions. Binding of Erbitux to EGFR interferes with ligand-mediated activation of the receptor’s intracellular tyrosine kinase activity and inhibits the EGFR-mediated signaling.

This results in the inhibition of cell growth, induction of apoptosis, decreased matrix metalloprotease secretion, and reduced vascular endothelial growth factor production. Erbitux may also induce the activation of the immune system through antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.